What is the 13F Pro Quality Score for DVAX?

13F Pro ranks DYNAVAX TECHNOLOGIES CORP (DVAX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View DVAX's current score at https://13fpro.ai/company/DVAX (free sign-up required for the full ranking).

Which hedge funds own the most DVAX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of DVAX include BlackRock,, Deep Track Capital,, VANGUARD GROUP. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/DVAX as soon as new 13F filings post.

Where does 13F Pro source DVAX data?

All DYNAVAX TECHNOLOGIES CORP fundamentals and ownership data come directly from SEC EDGAR. DYNAVAX TECHNOLOGIES CORP files with the SEC under CIK 1029142. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is DVAX in?

DYNAVAX TECHNOLOGIES CORP (DVAX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is DVAX research updated on 13F Pro?

DVAX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

DYNAVAX TECHNOLOGIES CORP(DVAX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1029142 DVAX stock profile & AI dashboard →

13F Pro Quality Score

47.2/100

Rank #1,668 of 2,856 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

75.4/100

Profitability

17.4/100

Balance Sheet

24.6/100

Earnings Quality

81.3/100

Free Cash Flow

81.4/100

Institutional Flow

2.3/100

Revenue Scale

30.6/100

Dilution Risk

9.2/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why DVAX Scores 47/100

exact factor attribution · 2026-07-01

DVAX's composite is driven by revenue growth and free cash flow, held back by profitability and scale. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+5.1 pts

75th pct

Free cash flow

+4.7 pts

81th pct

Earnings quality

+3.1 pts

81th pct

Earnings growth

-1.0 pts

30th pct

Shareholder dilution

-2.0 pts

9th pct

Institutional flow

-2.4 pts

2th pct

Capital efficiency

-2.5 pts

25th pct

Scale

-2.9 pts

31th pct

Profitability

-4.9 pts

17th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

DVAX Stock Analysis & AI Quality Score

Data updated 2026-07-26

AI stock analysis and institutional research for DYNAVAX TECHNOLOGIES CORP (DVAX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores DVAX at 47.2/100 on a 32-signal composite quality model, placing it at rank #1,668 of 2,856 stocks — the bottom half of the AI-ranked universe. DVAX scores in the top quartile across free cash flow (81.4), earnings quality (81.3), revenue growth (75.4). Areas of concern include institutional flow (2.3) and profitability (17.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 9.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q3 2025), DYNAVAX TECHNOLOGIES CORP reports quarterly revenue of $94.9M, net income of $26.9M, free cash flow of $32.6M. Top institutional holders of DVAX by reported 13-F value include BlackRock, Deep Track Capital, VANGUARD GROUP, based on the most recent SEC filings. DVAX trades on the Nasdaq exchange and files with the SEC under CIK 1029142. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate DVAX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for DYNAVAX TECHNOLOGIES CORP directly from SEC EDGAR. DYNAVAX TECHNOLOGIES CORP's 13F Pro composite quality score has ranged between 18 and 77 since 2021, currently 47.2 — an improving long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about DYNAVAX TECHNOLOGIES CORP

Quirks, history, and lore behind DVAX — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biopharmaceutical company · small-cap · listed on Nasdaq · headquartered in the San Francisco Bay Area.
2
The Numbers
Annual revenue in the tens of millions of dollars — not exactly a pharma giant — with most of its cash tied to a single commercial vaccine and ongoing R&D burn.
3
The History
Founded in the late 1990s, the company spent years quietly developing immunology platform technology before landing its first FDA-approved product.
4
The Secret
Its core expertise is toll-like receptor (TLR) agonists — immune-system nudgers used as adjuvants to make vaccines hit harder and last longer.
5
The Lore
It got a massive boost during the COVID-19 pandemic, supplying its adjuvant technology to help turbocharge other companies' vaccine programs worldwide.
6
The Giveaway
Its FDA-approved HEPLISAV-B is a two-dose hepatitis B vaccine — a notable upgrade on the old three-dose standard — and the flagship product of this Emeryville, California immunology shop.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q3 2025

$94.9M

Net Income

Q3 2025

$26.9M

Free Cash Flow

Q3 2025

$32.6M

ROIC

Q3 2025

15.9%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+19.4% YoY

$277.2MFY 2024

FY21 $439.4MFY22 $722.7MFY23 $232.3MFY24 $277.2M

Net Income

+527.4% YoY

$27.3MFY 2024

FY21 $76.7MFY22 $293.2MFY23 $-6.4MFY24 $27.3M

Operating Income

+88.9% YoY

$-4.1MFY 2024

FY21 $134.5MFY22 $283.5MFY23 $-37.0MFY24 $-4.1M

EPS (Diluted)

+500.0% YoY

$0.20FY 2024

FY21 $0.57FY22 $1.97FY23 $-0.05FY24 $0.20

Total Assets

-1.1% YoY

$986.3MFY 2024

FY21 $1.04BFY22 $985.9MFY23 $997.1MFY24 $986.3M

Total Debt

—FY 2024

FY21 $0.00FY22 —FY23 —FY24 —

Op. Cash Flow

-33.9% YoY

$66.5MFY 2024

FY21 $335.5MFY22 $62.7MFY23 $100.6MFY24 $66.5M

Free Cash Flow

-37.6% YoY

$60.2MFY 2024

FY21 $326.1MFY22 $55.6MFY23 $96.5MFY24 $60.2M

Metric	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Revenue	$277.2M +19.4%	$232.3M -67.9%	$722.7M +64.5%	$439.4M +844.0%	$46.6M +32.2%	$35.2M
Net Income	$27.3M +527.4%	$-6.4M -102.2%	$293.2M +282.1%	$76.7M +202.0%	$-75.2M +50.7%	$-152.6M
Operating Income	$-4.1M +88.9%	$-37.0M -113.1%	$283.5M +110.8%	$134.5M +296.7%	$-68.4M +49.3%	$-134.8M
EPS (Diluted)	$0.20 +500.0%	$-0.05 -102.5%	$1.97 +245.6%	$0.57 +173.1%	$-0.78 +63.9%	$-2.16
Total Assets	$986.3M -1.1%	$997.1M +1.1%	$985.9M -5.1%	$1.04B +194.2%	$353.3M +26.6%	$279.1M
Total Debt	—	—	—	$0.00 -100.0%	$179.8M +0.7%	$178.6M
Operating Cash Flow	$66.5M -33.9%	$100.6M +60.3%	$62.7M -81.3%	$335.5M +463.7%	$-92.3M +23.9%	$-121.3M
Free Cash Flow	$60.2M -37.6%	$96.5M +73.6%	$55.6M -83.0%	$326.1M +438.5%	$-96.3M +32.9%	$-143.7M

Get alerted when DVAX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for DYNAVAX TECHNOLOGIES CORP including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of DVAX

BlackRock, Inc.
$250.8M16,307,312 sh
Deep Track Capital, LP
$241.9M15,726,349 sh
VANGUARD GROUP INC
$123.5M8,027,448 sh
STATE STREET CORP
$110.2M7,164,163 sh
LINDEN ADVISORS LP
$90.4M86,598,000 sh
Shaolin Capital Management LLC
$57.1M38,905,000 sh
CITADEL ADVISORS LLC
$56.5M54,177,000 sh
Chicago Capital, LLC
$53.4M3,469,580 sh
RENAISSANCE TECHNOLOGIES LLC
$51.3M3,337,533 sh
DIMENSIONAL FUND ADVISORS LP
$46.3M3,011,086 sh

Fund	Value	Shares
BlackRock, Inc.	$250.8M	16,307,312
Deep Track Capital, LP	$241.9M	15,726,349
VANGUARD GROUP INC	$123.5M	8,027,448
STATE STREET CORP	$110.2M	7,164,163
LINDEN ADVISORS LP	$90.4M	86,598,000
Shaolin Capital Management LLC	$57.1M	38,905,000
CITADEL ADVISORS LLC	$56.5M	54,177,000
Chicago Capital, LLC	$53.4M	3,469,580
RENAISSANCE TECHNOLOGIES LLC	$51.3M	3,337,533
DIMENSIONAL FUND ADVISORS LP	$46.3M	3,011,086

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put DVAX on your watchlist

Track score changes the day DYNAVAX TECHNOLOGIES CORP files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is DVAX a good stock to buy?

13F Pro's AI-powered analysis of DYNAVAX TECHNOLOGIES CORP (DVAX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for DVAX are available on the DVAX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. DVAX is classified as a small company.

Which hedge funds own DVAX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling DVAX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of DYNAVAX TECHNOLOGIES CORP's investment landscape.